Ionis Pharmaceuticals, Inc. financials
Key figures from Ionis Pharmaceuticals, Inc.'s filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | $268M | $452M | -40.7% |
| Net income | -$115M | $124M | -192.8% |
| Free cash flow | $549M | $139M | +295.2% |
| Gross margin | 99.0% | 99.1% | -0.1 pts |
| Operating margin | -38.2% | 30.9% | -69.1 pts |
| Net margin | -42.8% | 27.3% | -70.1 pts |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2025 | $944M | -$381M | -40.4% | -$320M | -$2.38 |
| FY Dec 2024 | $705M | -$454M | -64.4% | -$546M | -$3.04 |
| FY Dec 2023 | $788M | -$366M | -46.5% | -$331M | -$2.56 |
| FY Dec 2022 | $587M | -$270M | -45.9% | -$290M | -$1.90 |
| FY Dec 2021 | $810M | -$29M | -3.5% | $19M | -$0.20 |
All figures from company filings with the SEC.